Effectiveness of Nirsevimab in High-Risk Children Under 24 Months for Prevention of Respiratory Syncytial Virus Infection: A Systematic Review and Meta-Analysis
Authors:
- Ye Kyung KimYKYe Kyung Kim
- Erdenetuya BolormaaEBErdenetuya Bolormaa
- Ui Yoon ChoiUCUi Yoon Choi
- Hyun Mi KangHKHyun Mi Kang
- Ji-Man KangJKJi-Man Kang
- Joon-Sik ChoiJCJoon-Sik Choi
- Ki Wook YunKYKi Wook Yun
- Byung Ok KwakBKByung Ok Kwak
- Seung-Ah ChoeSCSeung-Ah Choe
- Young June ChoeYCYoung June Choe
- Jin LeeJLJin Lee
- Soo-Han ChoiSCSoo-Han Choi
Open Access
- 1 January 2026
- journal article
- review article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Abstract
Kim YK, et al. J Korean Med Sci. 2026 Dec;41:e317. https://doi.org/10.3346/jkms.2026.41.e317Keywords
Funding Information
- Korea Health Industry Development Institute (RS-2025-02304519)
This publication has 26 references indexed in Scilit:
- Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): a retrospective observational studyThe Lancet Infectious Diseases, 2025
- Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysisThe Lancet Child & Adolescent Health, 2025
- Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Journal of Infection, 2025
- Effectiveness of nirsevimab in reducing hospitalizations in emergency departments due to bronchiolitis among infants under 3 months: a retrospective studyEuropean Journal of Pediatrics, 2025
- Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: a test-negative case–control studyThe Lancet Regional Health - Europe, 2024
- Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infantsNature Medicine, 2023
- Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and ChildrenJAMA Network Open, 2023
- Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trialsThe Lancet Child & Adolescent Health, 2023
- Outpatient RSV lower respiratory infections among high‐risk infants and other pediatric populationsPediatric Pulmonology, 2010
- Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent WheezingThe Journal of Pediatrics, 2007